160 related articles for article (PubMed ID: 16451081)
1. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
Wendt MD; Shen W; Kunzer A; McClellan WJ; Bruncko M; Oost TK; Ding H; Joseph MK; Zhang H; Nimmer PM; Ng SC; Shoemaker AR; Petros AM; Oleksijew A; Marsh K; Bauch J; Oltersdorf T; Belli BA; Martineau D; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2006 Feb; 49(3):1165-81. PubMed ID: 16451081
[TBL] [Abstract][Full Text] [Related]
2. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
4. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.
Sheppard GS; Wang J; Kawai M; Fidanze SD; BaMaung NY; Erickson SA; Barnes DM; Tedrow JS; Kolaczkowski L; Vasudevan A; Park DC; Wang GT; Sanders WJ; Mantei RA; Palazzo F; Tucker-Garcia L; Lou P; Zhang Q; Park CH; Kim KH; Petros A; Olejniczak E; Nettesheim D; Hajduk P; Henkin J; Lesniewski R; Davidsen SK; Bell RL
J Med Chem; 2006 Jun; 49(13):3832-49. PubMed ID: 16789740
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
7. Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation.
Natarajan A; Guo Y; Harbinski F; Fan YH; Chen H; Luus L; Diercks J; Aktas H; Chorev M; Halperin JA
J Med Chem; 2004 Oct; 47(21):4979-82. PubMed ID: 15456240
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Park CM; Bruncko M; Adickes J; Bauch J; Ding H; Kunzer A; Marsh KC; Nimmer P; Shoemaker AR; Song X; Tahir SK; Tse C; Wang X; Wendt MD; Yang X; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2008 Nov; 51(21):6902-15. PubMed ID: 18841882
[TBL] [Abstract][Full Text] [Related]
10. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
Sleebs BE; Czabotar PE; Fairbrother WJ; Fairlie WD; Flygare JA; Huang DC; Kersten WJ; Koehler MF; Lessene G; Lowes K; Parisot JP; Smith BJ; Smith ML; Souers AJ; Street IP; Yang H; Baell JB
J Med Chem; 2011 Mar; 54(6):1914-26. PubMed ID: 21366295
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
13. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
15. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
Zhou YL; Hu WX; Lü YP; Qiu LN; Wang WS; Yang ZY; Liu JD; Rao GW
Yao Xue Xue Bao; 2007 Jan; 42(1):26-34. PubMed ID: 17520803
[TBL] [Abstract][Full Text] [Related]
16. Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents.
Lobb KL; Hipskind PA; Aikins JA; Alvarez E; Cheung YY; Considine EL; De Dios A; Durst GL; Ferritto R; Grossman CS; Giera DD; Hollister BA; Huang Z; Iversen PW; Law KL; Li T; Lin HS; Lopez B; Lopez JE; Cabrejas LM; McCann DJ; Molero V; Reilly JE; Richett ME; Shih C; Teicher B; Wikel JH; White WT; Mader MM
J Med Chem; 2004 Oct; 47(22):5367-80. PubMed ID: 15481975
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
18. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
Kogan NM; Rabinowitz R; Levi P; Gibson D; Sandor P; Schlesinger M; Mechoulam R
J Med Chem; 2004 Jul; 47(15):3800-6. PubMed ID: 15239658
[TBL] [Abstract][Full Text] [Related]
20. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
